HYPERFINE Stock Price, News & Analysis

Hyperfine, Inc. (Nasdaq: HYPR) announced it will release its third-quarter 2022 financial results on November 10, 2022. Following the release, management will conduct a conference call at 1:30 PM PT / 4:30 PM ET. Interested participants can register online to listen. Hyperfine is known for its innovative Swoop® system, the first portable MRI device cleared by the FDA, which allows for quick diagnostics and treatments in various healthcare settings, improving patient access to essential imaging services.

Hyperfine, Inc. (Nasdaq: HYPR) announced Maria Sainz as its new President and CEO, effective October 24, 2022. Sainz, with over 30 years of experience in the medical device sector, has previously led multiple companies and has been a board member since Hyperfine's Nasdaq listing. She aims to expand the adoption of Hyperfine's portable MRI system, Swoop, which is already installed in over 90 locations globally. The company seeks to enhance medical imaging access worldwide while maintaining a disciplined spending approach to drive growth.

Hyperfine (Nasdaq: HYPR) announced management's participation in two upcoming conferences. Scott Huennekens and Alok Gupta will present at the Gilmartin Group Emerging Growth Company Showcase on August 31, 2022, at 1:00 PM EDT. A live webcast will be available. Gupta and Khan Siddiqui will present at the 2022 Wells Fargo Healthcare Conference on September 8, 2022, at 9:10 AM EDT, with a live and archived version accessible online. Hyperfine is known for Swoop, the first FDA-cleared portable MRI system, enhancing patient access to diagnostic imaging.

Hyperfine, Inc. (Nasdaq: HYPR) reported Q2 2022 revenues of $1.533 million, up from $0.358 million in Q2 2021, reflecting strong adoption of its portable MRI system, Swoop. However, the company faced a net loss of $23.159 million, compared to a loss of $14.580 million in the same period last year. Hyperfine installed 9 new systems, bringing total installations to 47. The company anticipates 2022 revenues of $7 million to $8 million and plans to install 35 to 45 commercial units. Positive developments include FDA clearances for system enhancements and a partnership with Viz.ai for improved patient care.

Viz.ai has partnered with Hyperfine, Inc. (NASDAQ: HYPR) to enhance healthcare delivery by integrating AI-powered disease detection with Hyperfine's portable MRI system, Swoop. This collaboration aims to expedite neuroimaging, allowing clinicians to access MRI diagnostics at the patient's bedside, significantly reducing wait times and improving decision-making in time-critical situations. The partnership is expected to enhance patient outcomes and streamline clinical workflows, particularly in neuro ICUs, emphasizing the importance of timely medical intervention.

Hyperfine, Inc. (Nasdaq: HYPR) will announce its financial results for Q2 2022 on August 10, 2022, at a webcast starting at 1:30 p.m. PT / 4:30 p.m. ET. The company is known for Swoop®, the first FDA-cleared portable MRI system, aimed at enhancing patient access to critical imaging. Designed for versatility, Swoop provides rapid diagnostics in various settings, with high-quality images at lower costs.

Hyperfine, a pioneering medical device company, unveiled an advanced software upgrade for its Swoop® portable MRI system at HA Connect! on July 14, 2022. This enhancement allows brain scans for young hydrocephalus patients in under three minutes without ionizing radiation, addressing health risks associated with CT scans. With over 40,000 hospital admissions yearly due to hydrocephalus, this software aims to improve diagnostic efficiency and patient safety. The FDA recently cleared this update, demonstrating Hyperfine's commitment to innovative healthcare solutions.

Hyperfine, Inc. (Nasdaq: HYPR) announces a leadership transition as Dave Scott steps down as President and CEO, effective July 29, 2022, due to personal reasons. Scott Huennekens, current Executive Chairperson, will serve as interim President and CEO while a search for a long-term leader is conducted. Hyperfine reaffirms its 2022 financial guidance, projecting revenues between $10 to $12 million and installation of 50 to 60 commercial units. The company emphasizes the ongoing expansion of its portable MRI system, Swoop, and its commitment to enhancing global access to medical imaging.

Hyperfine, Inc. (Nasdaq: HYPR) announced that its Swoop® Portable MR Imaging System™ has received registration in Australia and New Zealand. This makes the device, which is the first FDA-cleared portable MRI, available for purchase in these regions. Quantum HealthCare will distribute the Swoop system, enhancing Hyperfine's market entry. The system, already utilized at Alfred Health for point-of-care brain scans, improves patient outcomes by reducing transport needs. The device can operate on standard power and requires no special room setups, making it ideal for remote areas.